• Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22067563).
  
• Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=22067563).
  

PubMed=22067563; DOI=10.1093/neuonc/nor195
Wakimoto H., Mohapatra G., Kanai R., Curry W.T. Jr., Yip S., Nitta M., Patel A.P., Barnard Z.R., Stemmer-Rachamimov A.O., Louis D.N., Martuza R.L., Rabkin S.D.
Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.
Neuro-oncol. 14:132-144(2012)

PubMed=24726434; DOI=10.1016/j.cell.2014.02.030
Suva M.L., Rheinbay E., Gillespie S.M., Patel A.P., Wakimoto H., Rabkin S.D., Riggi N., Chi A.S., Cahill D.P., Nahed B.V., Curry W.T. Jr., Martuza R.L., Rivera M.N., Rossetti N., Kasif S., Beik S., Kadri S., Tirosh I., Wortman I., Shalek A.K., Rozenblatt-Rosen O., Regev A., Louis D.N., Bernstein B.E.
Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells.
Cell 157:580-594(2014)

PubMed=27564115; DOI=10.18632/oncotarget.11589
Wilson T.J., Zamler D.B., Doherty R., Castro M.G., Lowenstein P.R.
Reversibility of glioma stem cells' phenotypes explains their complex in vitro and in vivo behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery tool.
Oncotarget 7:63020-63041(2016)